Shanshan Xu - 29 Oct 2026 Form 4 Insider Report for Bambusa Therapeutics, Inc.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
02 Nov 2026, 16:01:36 UTC
Next SEC filing
02 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan I. Lieber, as attorney-in-fact
Filing notes and source

Key filing fact

Shanshan Xu filed Form 4 for Bambusa Therapeutics, Inc. on 02 Nov 2026.

Key facts

  • This page summarizes Shanshan Xu's Form 4 filing for Bambusa Therapeutics, Inc..
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 02 Nov 2026, 16:01.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002160743 Primary reporting owner

Xu Shanshan

Relationship
Co-Founder, Chief Executive Officer, President, and Chairperson, Director, 10%+ Owner
Address
C/O BAMBUSA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, FLOOR 7, BOSTON
Signature
/s/ Jonathan I. Lieber, as attorney-in-fact
Signature date
02 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+379,102
Change %
Price
$0.000000*
Shares after
379,102
Date
29 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
379,102
Exercise price
$16.00
Footnotes
F1
No ticker transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares
+758,204
Change %
Price
$0.000000*
Shares after
758,204
Date
29 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
758,204
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean October 29, 2026.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest upon the Administrator (as defined in the Issuer's 2026 Equity Incentive Plan) determining and certifying the achievement of the weighted average price of a share of the Issuer's common stock equals or exceeds $32 for any period of 30 consecutive trading days following April 1, 2027 and prior to April 1, 2030.

SEC remarks

Co-Founder, Chief Executive Officer, President, and Chairperson

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .